Cargando…

Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients

Chimeric antigen receptor (CAR) T cell expansion and persistence emerged as key efficacy determinants in cancer patients. These features are typical of early-memory T cells, which can be enriched with specific manufacturing procedures, providing signal one and signal two in the proper steric conform...

Descripción completa

Detalles Bibliográficos
Autores principales: Arcangeli, Silvia, Falcone, Laura, Camisa, Barbara, De Girardi, Federica, Biondi, Marta, Giglio, Fabio, Ciceri, Fabio, Bonini, Chiara, Bondanza, Attilio, Casucci, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317024/
https://www.ncbi.nlm.nih.gov/pubmed/32636841
http://dx.doi.org/10.3389/fimmu.2020.01217
_version_ 1783550539683856384
author Arcangeli, Silvia
Falcone, Laura
Camisa, Barbara
De Girardi, Federica
Biondi, Marta
Giglio, Fabio
Ciceri, Fabio
Bonini, Chiara
Bondanza, Attilio
Casucci, Monica
author_facet Arcangeli, Silvia
Falcone, Laura
Camisa, Barbara
De Girardi, Federica
Biondi, Marta
Giglio, Fabio
Ciceri, Fabio
Bonini, Chiara
Bondanza, Attilio
Casucci, Monica
author_sort Arcangeli, Silvia
collection PubMed
description Chimeric antigen receptor (CAR) T cell expansion and persistence emerged as key efficacy determinants in cancer patients. These features are typical of early-memory T cells, which can be enriched with specific manufacturing procedures, providing signal one and signal two in the proper steric conformation and in the presence of homeostatic cytokines. In this project, we exploited our expertise with paramagnetic beads and IL-7/IL-15 to develop an optimized protocol for CAR T cell production based on reagents, including a polymeric nanomatrix, which are compatible with automated manufacturing via the CliniMACS Prodigy. We found that both procedures generate similar CAR T cell products, highly enriched of stem cell memory T cells (T(SCM)) and equally effective in counteracting tumor growth in xenograft mouse models. Most importantly, the optimized protocol was able to expand CAR T(SCM) from B-cell acute lymphoblastic leukemia (B-ALL) patients, which in origin were highly enriched of late-memory and exhausted T cells. Notably, CAR T cells derived from B-ALL patients proved to be as efficient as healthy donor-derived CAR T cells in mediating profound and prolonged anti-tumor responses in xenograft mouse models. On the contrary, the protocol failed to expand fully functional CAR T(SCM) from patients with pancreatic ductal adenocarcinoma, suggesting that patient-specific factors may profoundly affect intrinsic T cell quality. Finally, by retrospective analysis of in vivo data, we observed that the proportion of T(SCM) in the final CAR T cell product positively correlated with in vivo expansion, which in turn proved to be crucial for achieving long-term remissions. Collectively, our data indicate that next-generation manufacturing protocols can overcome initial T cell defects, resulting in T(SCM)-enriched CAR T cell products qualitatively equivalent to the ones generated from healthy donors. However, this positive effect may be decreased in specific conditions, for which the development of further improved protocols and novel strategies might be highly beneficial.
format Online
Article
Text
id pubmed-7317024
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73170242020-07-06 Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients Arcangeli, Silvia Falcone, Laura Camisa, Barbara De Girardi, Federica Biondi, Marta Giglio, Fabio Ciceri, Fabio Bonini, Chiara Bondanza, Attilio Casucci, Monica Front Immunol Immunology Chimeric antigen receptor (CAR) T cell expansion and persistence emerged as key efficacy determinants in cancer patients. These features are typical of early-memory T cells, which can be enriched with specific manufacturing procedures, providing signal one and signal two in the proper steric conformation and in the presence of homeostatic cytokines. In this project, we exploited our expertise with paramagnetic beads and IL-7/IL-15 to develop an optimized protocol for CAR T cell production based on reagents, including a polymeric nanomatrix, which are compatible with automated manufacturing via the CliniMACS Prodigy. We found that both procedures generate similar CAR T cell products, highly enriched of stem cell memory T cells (T(SCM)) and equally effective in counteracting tumor growth in xenograft mouse models. Most importantly, the optimized protocol was able to expand CAR T(SCM) from B-cell acute lymphoblastic leukemia (B-ALL) patients, which in origin were highly enriched of late-memory and exhausted T cells. Notably, CAR T cells derived from B-ALL patients proved to be as efficient as healthy donor-derived CAR T cells in mediating profound and prolonged anti-tumor responses in xenograft mouse models. On the contrary, the protocol failed to expand fully functional CAR T(SCM) from patients with pancreatic ductal adenocarcinoma, suggesting that patient-specific factors may profoundly affect intrinsic T cell quality. Finally, by retrospective analysis of in vivo data, we observed that the proportion of T(SCM) in the final CAR T cell product positively correlated with in vivo expansion, which in turn proved to be crucial for achieving long-term remissions. Collectively, our data indicate that next-generation manufacturing protocols can overcome initial T cell defects, resulting in T(SCM)-enriched CAR T cell products qualitatively equivalent to the ones generated from healthy donors. However, this positive effect may be decreased in specific conditions, for which the development of further improved protocols and novel strategies might be highly beneficial. Frontiers Media S.A. 2020-06-19 /pmc/articles/PMC7317024/ /pubmed/32636841 http://dx.doi.org/10.3389/fimmu.2020.01217 Text en Copyright © 2020 Arcangeli, Falcone, Camisa, De Girardi, Biondi, Giglio, Ciceri, Bonini, Bondanza and Casucci. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Arcangeli, Silvia
Falcone, Laura
Camisa, Barbara
De Girardi, Federica
Biondi, Marta
Giglio, Fabio
Ciceri, Fabio
Bonini, Chiara
Bondanza, Attilio
Casucci, Monica
Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
title Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
title_full Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
title_fullStr Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
title_full_unstemmed Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
title_short Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
title_sort next-generation manufacturing protocols enriching t(scm) car t cells can overcome disease-specific t cell defects in cancer patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317024/
https://www.ncbi.nlm.nih.gov/pubmed/32636841
http://dx.doi.org/10.3389/fimmu.2020.01217
work_keys_str_mv AT arcangelisilvia nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients
AT falconelaura nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients
AT camisabarbara nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients
AT degirardifederica nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients
AT biondimarta nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients
AT gigliofabio nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients
AT cicerifabio nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients
AT boninichiara nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients
AT bondanzaattilio nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients
AT casuccimonica nextgenerationmanufacturingprotocolsenrichingtscmcartcellscanovercomediseasespecifictcelldefectsincancerpatients